Aditya Kotecha, MD, MBA

My research is centered on improving outcomes in critically ill patients through evidence-based innovations in pulmonary and critical care medicine. Key areas of interest include:

• Extracorporeal Membrane Oxygenation (ECMO): Clinical optimization, patient selection, and outcomes in adult ECMO support. I am particularly interested in applying predictive analytics to identify high-risk phenotypes and guide individualized therapy.

• Critical Care Pharmacotherapy & Hemodynamics: Investigating the impact of weight-based vasopressor dosing and fluid responsiveness on mortality in septic shock and other ICU syndromes.

• Sarcoidosis and Interstitial Lung Diseases (ILD): Characterizing clinical phenotypes and long-term outcomes, with a focus on autoimmune-associated ILD such as Sjögren’s and IgG4-related disease.

• Hereditary Hemorrhagic Telangiectasia (HHT): Therapeutic use of targeted agents such as bevacizumab for refractory epistaxis and GI bleeding, and interdisciplinary approaches to diagnosis and care.

• Point-of-Care Ultrasound and Critical Care Echocardiography: Advancing bedside diagnostics through structured POCUS curricula, quality assurance, and integration of ultrasound into decision-making in the ICU.

• Healthcare AI & Safety: As a member of the Collaboration for Health AI (CHAI), I am engaged in developing frameworks for safe, trustworthy implementation of machine learning tools in acute care settings.

Peer-Reviewed Publications

1. Krishnamoorthy G, Kotecha A, Pimentel J. Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy. BMJ Case Rep. 2019;12(1).

2. Yousif P, Kotecha A, Thakur A, Ismail HM. A rare case of diffuse large B cell lymphoma presenting as a cardiac mass. Am J Case Rep. 2019;20:1821–1825.

3. Kotecha A, et al. Cardiorenal syndrome in sepsis: A narrative review. J Crit Care. 2018;43:122–127.

4. Kotecha AA, et al. Clinical outcomes of weight-based norepinephrine dosing in underweight and morbidly obese patients: A propensity-matched analysis. J Intensive Care Med. 2018.

5. Vallabhajosyula S, Jentzer JC, Kotecha AA, et al. A novel vasopressor-driven mortality prediction model in septic shock. Ann Intensive Care. 2018;8:112.

6. Iyer VN, Apala DR, Pannu BS, Kotecha A, et al. Intravenous bevacizumab for refractory HHT-related epistaxis and GI bleeding. Mayo Clin Proc. 2018;93(2):155–166.

7. Alkinj B, Apala DR, Kotecha A, et al. Saddle vs nonsaddle PE: Presentation, hemodynamics, outcomes. Mayo Clin Proc. 2017;92(10):1511–1518.

8. Krishna A, Pervaiz A, Kotecha A, et al. C. difficile infection in hospitals, LTCFs, and clinics. Am J Infect Control.2017.

9. Pannu BS, Apala DR, Kotecha A, et al. MMPH in tuberous sclerosis—long-term stability. Respir Med Case Rep.2017;20:113–115.

10. Jain T, John J, Kotecha A, et al. CMV infection in autologous SCT recipients in rituximab era. Ann Hematol.2016;95(8):1323–1327.

• Outstanding Scholarly Achievement Award, Detroit Medical Center/Sinai Grace Hospital, 2018.
  Recognized for exceptional academic performance and scholarly contributions during internal medicine residency.

• Star Research Award, Society of Critical Care Medicine (SCCM) Annual Congress, 2018.
  Awarded for impactful research on vasopressor dosing in septic shock.

• Outstanding Poster Award, CHEST Annual Meeting, 2017.
  Selected for excellence in clinical research presentation at an international conference.

• First Place – Oral Clinical Vignette, American College of Physicians (ACP) Michigan Chapter, 2017.
  Top honor for clinical case presentation highlighting rare manifestations of IgG4-related disease.

• Best Overall Monthly Exam Performer, Detroit Medical Center/Sinai Grace Hospital, 2017.
  Awarded for consistent academic excellence during internal medicine training.